Don’t let patients with early-stage lung cancer recur
Predict and prevent recurrence in patients with early-stage NSCLC with DetermaRx™.
DetermaRx is a 14-gene molecular stratification test that helps identify which patients with stage I and IIA non-squamous non-small cell lung cancer have a high risk of recurrence and may benefit from adjuvant chemotherapy.
DetermaRx is appropriate for all patients with stage IA, IB or IIA non-squamous NSCLC with a tumor size of less than 5 cm and with no nodal involvement (N0), who have undergone surgical resection and are now being considered for chemotherapy in the next stage of their care.
DetermaRx testing can be performed on any NSCLC that has been resected. You’ll need to send tumor tissue to Oncocyte’s lab, where the molecular signature is analyzed to stratify your patient’s risk. EGFR mutation analysis is also available from the same tissue sample. Both results come back in time to facilitate post-operative discussion with patients about the potential benefit of adjuvant chemotherapy.
DetermaRx has been validated in two independent cohorts with close to 1400 patients. DetermaRx outperformed NCCN criteria in identifying patients at high risk for mortality from stage IA, IB, and IIB non-squamous NSCLC1.
In a single institution prospective study, patients identified by DetermaRx as high-risk and who were treated with adjuvant chemotherapy had 91.7% 5-year disease-free survival compared to 48.9% 5-year DFS for high-risk patients who did not receive chemotherapy2. In a study of physician practices, DetermaRx results led to a change in treatment recommendation for 30% of patients3.
1. Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
2. Dormady, et al. (2015) The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol 20:59.
3. Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
Identify which early-stage patients can benefit from chemotherapy
“In medical oncology, data is very important, especially reliable data. The prospective validation of DetermaRx gives me confidence to use chemotherapy in the subset of patients that need it. And it allows the patients also to feel more confident taking some risks by knowing the benefit they obtain.”
Alejandro Calvo, MD
Medical Oncologist, Kettering Cancer Center
DetermaRx is paving the way for improved stage I and IIA NSCLC outcomes, giving oncologists a way to more confidently identify and treat patients who likely harbor micrometastatic disease.
DetermaRx offers insight into the best possible treatment decisions for your patients and may minimize the risk of under-treating patients who could benefit from chemotherapy and overtreating those for whom surgery is likely curative.
Becoming an early adopter of this innovative predictive test can improve your confidence in patient care and continuity of management.
DetermaRx is a 14-gene molecular treatment stratification test to identify patients with Stage IA, IB and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy following surgical resection.
DetermaRx is appropriate for all patients with Stage IA, IB or IIA non-squamous non-small cell lung cancer (NSCLC) with a tumor size of less than 5 cm and with no nodal involement (N0), who have undergone surgical resection and are now being considered for chemotherapy in the next stage of their care.
Results classify patients into low, intermediate, or high risk of disease recurrence. In a non-randomized, prospective study of 250 patients who were surgically resected at a single institution, patients in the high- and intermediate-risk categories who were treated with adjuvant chemotherapy had significantly better survival than high- and intermediate-risk patients who did not receive chemotherapy.
DetermaRx has been clinically validated in two independent cohorts with close to 1400 patients (Kratz et al, Lancet, 2012). A prospective study found that test-identified high/intermediate risk patients who were treated with adjuvant platinum-based chemotherapy had 91.7% 5-year disease-free survival (DFS) compared to 48.9% 5-year DFS for high/intermediate risk patients who did not receive chemotherapy. DetermaRx-identified low-risk patients had a disease-free survival (DFS) of 93.8% without adjuvant chemotherapy (Woodard et al, Clinical Lung Cancer, 2018). The significant difference in survival between treated vs. untreated high/intermediate-risk patients was reinforced in an expanded 250-patient prospective cohort, in which most patients were stage IA. (Woodard et al, North America Conference on Lung Cancer, 2020). A complete list of publications is available here.
You can register for an Oncocyte account here.
You may then order the DetermaRx test, track testing progress and access test results in your physician portal. You can also contact us at 1-844-ONCOCYTE or email@example.com to set up an account.
Yes. EGFR mutation testing (exons 18-21) is available from the same tissue sample. You may opt into EGFR testing when your order DetermaRx.
Oncocyte will provide a FFPE tissue shipping kit with detailed sample preparation and shipping instructions. We accept a tissue block or slides.
Results are typically ready within 10 business days from the time we receive the specimen.
Yes. If you opt into EGFR mutation testing when you order DetermaRx, you will receive a consolidated report with both DetermaRx and EGFR results.
We accept all forms of insurance including Medicare. Medicare covers the DetermaRx test, but we are currently out of network with other insurances. Once we have completed a patient’s test, we send them a letter explaining our insurance and financial assistance process. Patients who would like to be pre-qualified for financial assistance, or have any questions regarding insurance billing, can contact us at 1-844-662-6298.
- SEER data.
- Chansky, et al. (2017) The IASLC Lung Cancer Staging Project: External validation of the revision of the TNM stage groupings in the eight edition of the TNM classification of lung cancer. J Thorac Oncol 12:1109.
- Kratz, et al. (2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international studies. Lancet 379:823.
- Woodard, et al. (2018) Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clinical Lung Cancer 19:58.
- Woodard, et al. (2020) Molecular risk stratification is independent of EGFR mutation status in identifying early stage non-squamous non-small cell lung cancer patients at risk for recurrence and likely to benefit from adjuvant chemotherapy. Abstract presented at 2020 North America Conference on Lung Cancer.